key: cord-0791835-v5jlute9
authors: Alitongbieke, Gulimiran; Li, Xiu-min; Wu, Qi-Ci; Lin, Zhi-Chao; Huang, Jia-Fu; Xue, Yu; Liu, Jing-Na; Lin, Jin-Mei; Pan, Tao; Chen, Yi-Xuan; Su, Yi; Zhang, Guo-Guang; Leng, Bo; Liu, Shu-Wen; Pan, Yu-Tian
title: Effect of β-chitosan on the binding interaction between SARS-CoV-2 S-RBD and ACE2
date: 2020-09-18
journal: bioRxiv
DOI: 10.1101/2020.07.31.229781
sha: 172946c037eee29109df94f6aa2e6c6400cebff3
doc_id: 791835
cord_uid: v5jlute9

SARS-CoV-2 invades human respiratory epithelial cells via an interaction between its spike RBD protein (SARS-CoV-2 S-RBD) and the host cell receptor angiotensin converting enzyme II (ACE2). Blocking this interaction provides a potent approach to preventing and controlling SARS-CoV-2 infection. In this work, the ability of β-chitosan to block the binding interaction between SARS-CoV-2 S-RBD and ACE2 was investigated. The inhibitory effect of β-chitosan on inflammation induced by the SARS-CoV-2 S-RBD was also studied. Native-PAGE analysis indicated that β-chitosan could bind with ACE2 and the SARS-CoV-2 S-RBD and a conjugate of β-chitosan and ACE2 could no longer bind with the SARS-CoV-2 S-RBD. HPLC analysis suggested that a conjugate of β-chitosan and the SARS-CoV-2 S-RBD displayed high binding affinity without dissociation under high pressure (40 MPa) compared with that of β-chitosan and ACE2. Furthermore, immunofluorescent staining of Vero E6 cells and lungs from hACE2 mice showed that the presence of β-chitosan prevented SARS-CoV-2 S-RBD from binding to ACE2. Meanwhile, β-chitosan could dramatically suppress the inflammation caused by the presence of the SARS-CoV-2 S-RBD both in vitro and vivo. Moreover, the decreased expression of ACE2 caused by β-chitosan treatment was restored by addition of TAPI-1, an inhibitor of the transmembrane protease ADAM17. Our findings demonstrated that β-chitosan displays an antibody-like function capable of neutralizing the SARS-CoV-2 S-RBD and effectively preventing the binding of the SARS-CoV-2 S-RBD to ACE2. Moreover, ADAM17 activation induced by β-chitosan treatment can enhance the cleavage of the extracellular domain of ACE2, releasing the active ectodomain into the extracellular environment, which can prevent the binding, internalization, and degradation of ACE2 bound to the SARS-CoV-2 S-RBD and thus diminish inflammation. Our study provides an alternative avenue for preventing SARS-CoV-2 infection using β-chitosan.

that the presence of β -chitosan prevented SARS-CoV-2 S-RBD from binding to ACE2. In order to confirm whether the conjugate of β -chitosan and ACE2 (termed peak disappeared (Fig. 1d-) . This finding illustrated that the binding interaction S-RBD could not bind with ACE2, which was consistent with the above Native-PAGE 1 8 7

analysis. If β -chitosan~ACE2 dissociates at 40 MPa, the dissociated ACE2 would 1d-. However, the results in Fig. 1d -revealed a significant difference, indicating 1 9 0 that β -chitosan may interfere with the binding of the SARS-CoV-2 S-RBD to ACE2. SARS-CoV-2 S-RBD. IF analysis showed that ACE2 (red) and the SARS-CoV-2 S-RBD (green) S-RBD into Vero E6 cells (Fig. 2a-) . Moreover, significant colocalization of ACE2 2 0 7

with SARS-CoV-2 S-RBD was observed, implying that the SARS-CoV-2 S-RBD 2 0 8 binds to ACE2. When β -chitosan was added to the above system 10 min later, the 2 0 9

colocalization of ACE2 and SARS-CoV-2 S-RBD was reduced ( Fig. 2A-) ,

indicating that β -chitosan can prevent the binding of SARS-CoV-2 S-RBD to ACE2 2 1 1 exposed on the surface of Vero E6 cells. When β -chitosan and the SARS-CoV-2 2 1 2 S-RBD were added successively, the fluorescence intensities of ACE2 and the 2 1 3 SARS-CoV-2 S-RBD were also significantly reduced ( Fig. 2A- significantly and no colocalization was observed ( Fig. 2A-) , indicating that 2 1 9 β -chitosan demonstrates a neutralizing activity against the SARS-CoV-2 S-RBD. In 2 2 0 addition, it was also observed that the addition of β -chitosan alone significantly 2 2 1 decreased ACE2 expression in Vero E6 cells ( Fig. 2A-) . infected with the SARS-CoV-2 S-RBD (Fig. 2b) . Under the same parameters, 8000 2 2 5 cells were selected for analysis, and the colocalization of each experimental group 2 2 6 was compared. It was found that the colocalization of ACE2 and the SARS-CoV-2 2 2 7

S-RBD reached 33.6% (green line in Fig. 2b ) in Vero E6 cells following a 10 min 2 2 8

incubation with the SARS-CoV-2 S-RBD. When β -chitosan was added into the above could significantly diminish binding of the SARS-CoV-2 S-RBD with Vero E6 cells.

When mixtures of β -chitosan and the SARS-CoV-2 S-RBD were added to Vero E6 2 3 6 cells, the colocalization proportion was only 6.91%, which further supports the 2 3 7

conclusion that β -chitosan possesses neutralizing activity against the SARS-CoV-2 2 3 8 S-RBD. The expression levels of proteins involved in inflammation response signaling were all up-regulated significantly in Vero E6 cells following exposure to the 2 4 5 SARS-CoV-2 S-RBD for 10 min (Fig. 2c) . However, the expression of these proteins 2 4 6 was significantly down-regulated when Vero E6 cells exposed to the SARS-CoV-2 2 4 7

S-RBD were treated with β -chitosan for 10 min. These results indicated that the analyzed. The blue fluorescence signal from the β -chitosan dyed with CFW was 2 6 0 clearly distributed throughout the lungs of the mice (Fig. 3a) . These results indicated 2 6 1 that intranasally administered β -chitosan spreads throughout the lungs and attaches to 2 6 2 lung epithelial cells over time, confirming the utility of this delivery route for the 2 6 3 further evaluation of the antiviral effects of β -chitosan in the lung. The preventive and alleviative effect of β -chitosan on the morphological lesion induced by SARS-CoV-2 S-RBD in mouse lungs was further observed (Fig. 3b) . The 2 6 7 lungs of hACE2 mice infected with the SARS-CoV-2 S-RBD were obviously swollen. The above results suggested that β -chitosan treatment could significantly However, this decrease in ACE2 expression did not cause inflammation, on the effects, which implies that there might be another mechanism behind the decreased 3 1 4 expression of ACE2. It was reported that ACE2 could be cleaved by the ADAM17 whether the decreased ACE2 expression observed in this study is related to ADAM17 3 1 7 activity is unknown. Therefore, an ADAM17 inhibitor was used in the context of IF 3 1 8

and WB analyses to determine the role of this activity in this system.

The results of these experiments demonstrated that β -chitosan treatment

significantly decreased the expression of ACE2 in Vero E6 cells (Fig. 4) . When the 3 2 1 ADAM17 inhibitor (TAPI-1) was added in advance, the expression of ACE2 was giving the appearance of down-regulated ACE2 expression. Furthermore, the cleaved 3 3 0 extracellular domain of ACE2 retains its catalytic activity that degrades Ang II and 3 3 1 promotes antihypertensive effects. In this work, binding of SARS-CoV-2 S-RBD to β -chitosan was confirmed by In the human body, ACE is an angiotensin converting enzyme that catalyzes the it could be hypothesized that a system formed on the basis of the ACE-Ang -AT1R increase significantly, leading to a cytokine storm and multiple organ damage 7,22 .

Therefore, once an individual becomes infected by SARS-CoV-2, whether ACE2 is 3 5 7 beneficial or detrimental to the individual has become a hotly debated scientific issue.

Acute respiratory distress syndrome (ARDS) is one of the leading causes of death for 3 5 9

patients infected with COVID-19 and SARS. As a result, the relationship between 3 6 0 ARDS and ACE2 has attracted significant attention. Imai 23 found that ARDS lesions 3 6 1 in mice with the ACE2 gene knocked out were significantly more severe than those in Native-PAGE analysis demonstrated that ACE2 can be bound by β -chitosan, S-RBD were significantly decreased and inflammation responses were also activated. can catalyze the degradation of Ang II in the extracellular environment 19,26 . Thus, this 3 9 0 led to speculation with regard to whether there was a mechanism by which β -chitosan, 3 9 1 ADAM17, and ACE2 interact to drive an anti-SARS-CoV-2 effect. Accordingly, an 3 9 2 ADAM17 inhibitor (TAPI-1) was used to test this hypothesis, and the results 3 9 3

indicated that the decreased ACE2 expression level observed in the experimental 3 9 4 groups treated with β -chitosan was reversed upon addition of an ADAM17 inhibitor.

Compared with the no inhibitor group, the expression of ACE2 was significantly increased (* P < 0.05; * * P < 0.01). This finding suggested that β -chitosan can 3 9 7 activate ADAM17 to enhance the cleavage of the extracellular juxtamembrane region inflammation. This discovery that β -chitosan treatment can prevent the binding of the 4 0 3 Fig. 5 . Therefore, ADAM17 is a most Recently, Waradon Sungnak reported 27 that ACE2 and TMPRSS2 were highly SARS-CoV-2 was higher than that of pharyngeal swabs, suggesting that nasal degraded, displays good biocompatibility in the brain tissue of rats 28 . Kean also 4 1 5

found that β -chitosan exhibited no toxicity in acute toxicity tests performed with mice intravenous injection appears to be safe for humans. In this study, the infection has different pathogenic effects on WT mice and hACE2 mice, with especially high 4 2 7 pathogenicity in the hACE2 host, suggesting that the hACE2 mouse model is an

indispensable scientific tool for screening drugs against SARS-CoV-2.

In this work, the inhibitory effect of β -chitosan on the binding of the Other chemicals and reagents used in this work were of analytical reagent grade.

Binding of β -chitosan with ACE2 or SARS-CoV-2 S-RBD

In order to be compatible with the conditions required for HPLC analysis, precooled PBS and analyzed using flow cytometry (Flowsight, Merk Millipore, USA).

The instrument was adjusted according to a previously reported procedure 33 . The Paraffin sections were dewaxed into water, washed with distilled water, and dried. For immunofluorescence on cell culture, cells grown on glass cover-slips were anti-rabbit IgG (1:400) was added at room temperature for 1 h.

For section immunofluorescence, fresh samples were isolated and fixed in 4% UK) were used. Slides were subjected to standard immunohistochemistry staining.

Native-PAGE analysis 5 2 9

A 6% resolving gel and a 5% condensing gel were used for Native-PAGE sample. The protein separation was accomplished by application of 100 V for 120 min.

The gel was visualized by silver staining following electrophoresis according to a Analytical SEC-HPLC was performed using an Agilent 1200 HPLC system or tissue lysates were separated using sodium dodecyl sulfate polyacrylamide gel immunoreactive products were observed using an Omega Lum C Gel Imaging system 5 5 7

(Aplegen, USA), and the protein signals were evaluated by IOD using Image J 5 5 8

software.

Statistical analysis 5 6 0

All data were analyzed with GraphPad Prism 8.0 software. Two-tailed Student's 5 6 1 t-tests were applied for statistical analysis. For all data, a two-sided P value < 0.05 5 6 2 was considered statistically significant (*P < 0.05, **P < 0.01). This work was financially supported by the National Natural Science Foundation of China (81903665) Fig. 4 Verification of β-chitosan-mediated activation of ADAM17 cleavage of ACE2.

a: Effect of ADAM17 inhibitor TAPI on the expression of ACE2 as detected by immunofluorescence. Cells were treated with 8 μM of an ADAM17 inhibitor TAPI or with PBS for 30 min, and the cells were then treated as shown in Table 1 . Scale bars, 50 μm (white). b: Expression levels of ACE2 and inflammation-related proteins were analyzed by Western blot. All groups were compared with the no TAPI-1 control group. Scale bars, 50 μm (white).

-β-chitosan: control group for testing SARS-CoV-2 S-RBD/ACE2 binding. SARS-CoV-2 gains entry into host cells via the binding and internalization of ACE2 in a clathrin-dependent manner. Thus, the levels of the extracellular juxtamembrane region of ACE2, which can catalyze the degradation of Ang II, are decreased, resulting in increased Ang II levels and elevated blood pressure 19 . Moreover, ADAM17 cleaves few extracellular domain of ACE2.

Meanwhile, the NF-κB and JNK signaling pathways are activated along with some related-inflammatory pathways.

The arrowheads indicate the proposed process. The "T" shaped arrows represent an inhibitory effect.

+β-chitosan: treatment group for testing SARS-CoV-2 S-RBD/ACE2 binding. In the presence of β-chitosan, SARS-CoV-2 S-RBD and ACE2 are bound and shielded by β-chitosan, which blocks the binding and subsequent internalization of SARS-CoV-2 S-RBD to ACE2. ADAM17 is activated by β-chitosan to enhance the cleavage of the extracellular domain of ACE2. The active ectodomain of ACE2 remains catalytically active and degrades Ang II, thus promoting maintenance of a stable blood pressure. In addition, the NF-κB and JNK signaling pathways are also inhibited. Tables   Table 1 Experimental 

These experiments were conducted to determine whether the conjugate of β-chitosan and ACE2 can bind to SARS-CoV-2 S-RBD (S-RBD). For the condition of excess ACE2 relative to β-chitosan, 1 μg of ACE2 was mixed and incubated with 2 μg, 4 μg, or 8 μg of β-chitosan for 20 min at 37°C , respectively. Then, 1 μg of S-RBD was added, followed by another 20 min co-incubation. Finally, Native-PAGE was used to analyze the samples. b: Native-PAGE analysis of the collected samples. (1). β-chitosan; (2). ACE2; (3). ACE2 + β-chitosan

The grey value of the co-incubation mixture of ACE2 with S-RBD (lane 6) was diminished significantly compared to that of ACE2 or S-RBD, respectively. d: HPLC analysis of the collected samples. All samples were mixed and incubated for 20 min at 37°C . However, samples (7) and (8) underwent addition of β-chitosan or S-RBD and another 20 min incubation at 37°C , based on samples (4) and (5), respectively. (1). ACE2; (2). S-RBD; (3). β-chitosan; (4) ACE2 + S-RBD

Single channel images of S-RBD, ACE2 and DAPI are shown. Moreover, a single overlapped image (the merge image) was merged and generated using the single channel images for S-RBD, ACE2, and DAPI. b: Effect of β-chitosan on S-RBD binding to ACE2 as determined using flow cytometry. Merge 1 was generated by merging the single channel images of S-RBD and ACE2. c: Western blot analysis of inflammation-related proteins. Cells were treated with S-RBD and/or β-chitosan as

SARS-CoV-2 S-RBD and/or β -chitosan were inoculated intranasally into hACE2 and 4 9 0WT mice at a dose of 10 mg/kg body weight, respectively, and an equal volume of 4 9 1 PBS was used as control. Following treatment, mice were dissected to collect 4 9 2 different tissues in order to observe any histopathological changes. When Vero E6 cells had grown to 80% confluency, they were treated according conformation. Science 367, 1260-+, doi:10.1126/science.abb2507 (2020). Chem 13, 3649-3655, doi:10.1016/j.bmc.2005.03.034 (2005) . Ges 61, 1936 -1939 , doi:DOI 10.1002 /cber.19280610862 (1928